Phase III Trial of TR115 vs Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma
The ongoing Phase III trial of TR115 against established therapies in relapsed/refractory peripheral T/NK-cell lymphoma is critical as it could redefine treatment standards in oncology. A successful outcome may significantly enhance TR115's market position and influence future treatment guidelines.
View Company Intelligence
Explore aggregated signals, assets, and competitive context for organizations linked to this signal.
AutoResearch
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 6/15/2026, 11:54:45 AM
Assessment confidence: 71% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.
Executive Thesis
The ongoing Phase III trial of TR115 against established therapies in relapsed/refractory peripheral T/NK-cell lymphoma is critical as it could redefine treatment standards in oncology. A successful outcome may significantly enhance TR115's market position and influence future treatment guidelines. Assessment grounded in 19 ranked evidence items (11 high-relevance).
Strategic Assessment
Success in this trial could enhance the competitive positioning of TR115 in the oncology market, influencing future treatment guidelines. The strongest clinical anchor is TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma (ClinicalTrials.gov), entity match (tr115); patient population match (refractory). In Oncology · EZH2 Inhibitor, 0 regulatory and 6 competitive items passed relevance filtering for TR115.
Competitive Pressure
The most relevant competitive pressure comes from Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma (Bristol Myers Squibb) — sponsor/company relevance (bristol myers squibb); patient population match (refractory).
Regulatory Outlook
Regulatory risk is concentrated around The trial's outcomes will be pivotal for TR115's regulatory approval and could lead to changes in labeling and treatment recommendations, impacting compliance and market access..
Key Risks
- Elevated medium regulatory exposure for TR115 could delay market entry or constrain labeling if agency review intensifies.
- Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.
- Signal severity is high — leadership review is warranted.
Key Opportunities
- If TR115 demonstrates superior efficacy, it could capture significant market share from current therapies, leading to increased revenue potential for the company. This trial's results may also affect competitive dynamics in the oncology sector.
- Upside for TR115 may improve if TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma (ClinicalTrials.gov) delivers favorable follow-through.
- Upside for TR115 may improve if Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That (ClinicalTrials.gov) delivers favorable follow-through.
- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients with advanced clear cell renal cell carcinoma (RCC).
- Upside for TR115 may improve if Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (ClinicalTrials.gov) delivers favorable follow-through.
What Would Change This Assessment
- This becomes more urgent if Monitor progression-free survival and overall survival results, as well as enrollment updates from the trial sites in China.
- Timeline shift beyond mid term would change urgency.
- A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.
Supporting Evidence
No evidence in this category.
TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma
ClinicalTrials.govhigh relevance
Entity match (tr115); Patient population match (refractory)
FDA document
View sourceTesting the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That
ClinicalTrials.govhigh relevance
Entity match (gemcitabine); Patient population match (refractory)
FDA document
View sourceRadiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma
ClinicalTrials.govhigh relevance
Patient population match (refractory)
FDA document
View sourceIbrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
ClinicalTrials.govhigh relevance
Patient population match (refractory)
FDA document
View sourceA Phase II Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
ClinicalTrials.govhigh relevance
Patient population match (refractory)
FDA document
View sourcePhase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
Bristol Myers Squibbhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Patient population match (refractory)
FDA document
View sourceMerck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View sourceLilly presents promising Phase 1 data for first-in-class type II JAK2 inhibitor in myelofibrosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Lilly)
Phase II Trial of Venetoclax and Rituximab in Older Patients With Mantle Cell Lymphoma
Humanexa Signalsmedium relevance
Moderate corpus alignment
Surufatinib trial initiated for adjuvant therapy in pancreatic neuroendocrine tumors
Humanexa Signalsmedium relevance
Moderate corpus alignment
Phase I/IIa Trial of MC1R-targeted Therapy with Nivolumab in Advanced Melanoma
Humanexa Signalsmedium relevance
Moderate corpus alignment
Lactylation and liquid-liquid phase separation related genes influence prognosis and immune characteristics of diffuse large B-cell lymphoma patients.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View sourceTebentafusp (IMCgp100), a first in class immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC) for HLA-A*02:01 positive uveal melanoma: Product review.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View sourceImmunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View sourceTrial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceUmbilical cord blood natural killer cells improve anti-GD2 antibody efficacy in neuroblastoma: from mouse to human.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceDeep learning based on CD3 histological slides for prediction of colon cancer outcome: analysis of three international stage III colon cancer cohorts.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Regunera
Precedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitiva
Competitors · threats
Loading competitive findings…
View full competitive analysisWhy this matters
The ongoing Phase III trial of TR115 against established therapies in relapsed/refractory peripheral T/NK-cell lymphoma is critical as it could redefine treatment standards in oncology. A successful outcome may significantly enhance TR115's market position and influence future treatment guidelines.
Affected entities
- TR115
- chidamide
- golidocitinib
- mitoxantrone liposome
- gemcitabine
- oncology market
Commercial impact
If TR115 demonstrates superior efficacy, it could capture significant market share from current therapies, leading to increased revenue potential for the company. This trial's results may also affect competitive dynamics in the oncology sector.
Regulatory impact
The trial's outcomes will be pivotal for TR115's regulatory approval and could lead to changes in labeling and treatment recommendations, impacting compliance and market access.
What to watch
Monitor progression-free survival and overall survival results, as well as enrollment updates from the trial sites in China.
Recommended action
Track for follow-up milestones; no immediate action required.